This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-consensus-estimate: Archive
FuelCell Energy (FCEL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
FuelCell Energy (FCEL) delivered earnings and revenue surprises of +40.25% and +6.55%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
FCELPositive Net Change EPMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Core & Main (CNM) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Core & Main (CNM) delivered earnings and revenue surprises of +12.99% and -1.29%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
CNMPositive Net Change AZZPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Designer Brands (DBI) Tops Q2 Earnings Estimates
by Zacks Equity Research
Designer Brands (DBI) delivered earnings and revenue surprises of +54.55% and -1.10%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
DBIPositive Net Change SFIXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Korn/Ferry (KFY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Korn/Ferry (KFY) delivered earnings and revenue surprises of +5.65% and +3.43%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
KFYNegative Net Change AYIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
What Makes York Water (YORW) a New Buy Stock
by Zacks Equity Research
York Water (YORW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
YORWPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Shattuck Labs (STTK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STTKNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Tilly's (TLYS) a New Buy Stock
by Zacks Equity Research
Tilly's (TLYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TLYSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Exponent (EXPO) Rating Upgrade to Buy
by Zacks Equity Research
Exponent (EXPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EXPOPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
MUFG (MUFG) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
MUFG (MUFG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MUFGPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
1st Source (SRCE) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
1st Source (SRCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SRCEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
OGE Energy (OGE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
OGE Energy (OGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OGEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Bain Capital Specialty (BCSF) a New Strong Buy Stock
by Zacks Equity Research
Bain Capital Specialty (BCSF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BCSFNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Enpro (NPO) a New Strong Buy Stock
by Zacks Equity Research
Enpro (NPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NPOPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Mueller Water Products (MWA) Rating Upgrade to Buy
by Zacks Equity Research
Mueller Water Products (MWA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MWAPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for Trip.com (TCOM): Will It Gain?
by Zacks Equity Research
Trip.com (TCOM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
TCOMPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Why Loar Holdings Inc. (LOAR) Might be Well Poised for a Surge
by Zacks Equity Research
Loar Holdings Inc. (LOAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LOARPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Wall Street Analysts See a 35.64% Upside in Inogen (INGN): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
INGNNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 39.8% Upside in Photronics (PLAB): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 39.8% upside potential for Photronics (PLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PLABNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ALGSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 26.76% Upside in Ategrity Specialty Insurance Company Holdings (ASIC): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Ategrity Specialty Insurance Company Holdings (ASIC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ASICPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Epam (EPAM) Could Rally 26.37%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Epam (EPAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EPAMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 62.07% Upside in Red Robin (RRGB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Red Robin (RRGB) points to a 62.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
RRGBPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MRSNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PHATPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 34.02% Upside in Salesforce.com (CRM): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Salesforce.com (CRM) points to a 34% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate